Bristol-Myers Squibb Co - ESG Rating & Company Profile powered by AI
This ESG score includes seventeen United Nations Sustainable Development Goals including: 'Clean Water & Sanitation', 'Industry, Innovation & Infrastructure' and 'Peace, Justice & Strong Institutions'. The webpage contains a zero-cost Sustainability analysis for Bristol-Myers Squibb Co. This ESG score for Bristol-Myers Squibb Co represents the company's transparency towards the UN SDGs.
Bristol-Myers Squibb Co in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.0; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.
8.0
High ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Bristol-Myers Squibb Co | 8.0 | High |
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Bristol-Myers Squibb Co have an accelerator or VC vehicle to help deliver innovation?
Does Bristol-Myers Squibb Co disclose current and historical energy intensity?
Does Bristol-Myers Squibb Co report the average age of the workforce?
Does Bristol-Myers Squibb Co reference operational or capital allocation in relation to climate change?
Does Bristol-Myers Squibb Co disclose its ethnicity pay gap?
Does Bristol-Myers Squibb Co disclose cybersecurity risks?
Does Bristol-Myers Squibb Co offer flexible work?
Does Bristol-Myers Squibb Co have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Bristol-Myers Squibb Co disclose the number of employees in R&D functions?
Does Bristol-Myers Squibb Co conduct supply chain audits?
Does Bristol-Myers Squibb Co disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Bristol-Myers Squibb Co conduct 360 degree staff reviews?
Does Bristol-Myers Squibb Co disclose the individual responsible for D&I?
Does Bristol-Myers Squibb Co disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Bristol-Myers Squibb Co disclose current and / or historical scope 2 emissions?
Does Bristol-Myers Squibb Co disclose water use targets?
Does Bristol-Myers Squibb Co have careers partnerships with academic institutions?
Did Bristol-Myers Squibb Co have a product recall in the last two years?
Does Bristol-Myers Squibb Co disclose incidents of discrimination?
Does Bristol-Myers Squibb Co allow for Work Councils/Collective Agreements to be formed?
Has Bristol-Myers Squibb Co issued a profit warning in the past 24 months?
Does Bristol-Myers Squibb Co disclose parental leave metrics?
Does Bristol-Myers Squibb Co disclose climate scenario or pathway analysis?
Does Bristol-Myers Squibb Co disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Bristol-Myers Squibb Co disclose the pay ratio of women to men?
Does Bristol-Myers Squibb Co support suppliers with sustainability related research and development?
Does Bristol-Myers Squibb Co disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Bristol-Myers Squibb Co reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Bristol-Myers Squibb Co involved in embryonic stem cell research?
Does Bristol-Myers Squibb Co disclose GHG and Air Emissions intensity?
Does Bristol-Myers Squibb Co disclose its waste policy?
Does Bristol-Myers Squibb Co report according to TCFD requirements?
Does Bristol-Myers Squibb Co disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Bristol-Myers Squibb Co disclose energy use targets?
Does Bristol-Myers Squibb Co disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Bristol-Myers Squibb Co have a policy relating to cyber security?
Have a different question?
Potential Risks for Bristol-Myers Squibb Co
These potential risks are based on the size, segment and geographies of the company.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.